Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428932 | PMC |
| http://dx.doi.org/10.5603/CJ.2021.0091 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in chronic limb-threatening ischaemia (SWEDEPAD 1): a multicentre, participant-masked, registry-based, randomised controlled trial.
Lancet
August 2025
Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Background: Drug-coated devices are frequently used in coronary and peripheral interventions, but their effect on amputation risk in peripheral artery disease is unclear. We assessed whether drug-coated devices affect the rate of above-ankle amputation in patients with chronic limb-threatening ischaemia undergoing infrainguinal endovascular revascularisation.
Methods: The Swedish Drug-Elution Trial in Peripheral Arterial Disease 1 (SWEDEPAD 1) was a pragmatic, nationwide, multicentre, participant-masked, registry-based, randomised controlled trial at 22 Swedish centres.
Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in patients with intermittent claudication (SWEDEPAD 2): a multicentre, participant-masked, registry-based, randomised controlled trial.
Lancet
August 2025
Department of Radiology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Radiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Background: Drug-coated devices are widely used to reduce restenosis after lower limb revascularisation in patients with peripheral artery disease, but their effect on patient-centred outcomes remains unclear. We assessed the effect of paclitaxel-coated devices on clinically important outcomes in patients with intermittent claudication undergoing infrainguinal endovascular revascularisation.
Methods: The Swedish Drug-Elution Trial in Peripheral Arterial Disease 2 (SWEDEPAD 2) was a pragmatic, nationwide, multicentre, participant-masked, registry-based, randomised controlled trial conducted at 22 Swedish vascular centres.
Drug-coated balloon angioplasty versus conventional angioplasty for symptomatic non-acute intracranial artery occlusion.
Front Neurol
August 2025
Department of Neurology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China.
Background And Objective: Non-acute intracranial artery occlusion (ICAO) is an important cause of recurrent ischemic stroke despite aggressive medical treatment. Conventional angioplasty has high incidences of perioperative complications and restenosis in treating these patients. Drug-coated balloon (DCB) treatment has shown superiority in preventing restenosis.
View Article and Find Full Text PDFDrug-Coated Balloons for Coronary Artery Disease: From Theory to Practice.
Curr Treat Options Cardiovasc Med
December 2025
Inova Center of Outcomes Research, 3300 Gallows Road, Falls Church, VA 22042, USA.
Purpose Of Review: The purpose of this work is to review the role of drug-coated balloons (DCBs) in contemporary coronary artery disease (CAD) management by focusing on its clinical indications and technical considerations, supported by updated insights from the International DCB Consensus Group.
Recent Findings: While percutaneous coronary intervention (PCI) and drug-eluting stents were initially the standard treatment for CAD, limitations such in-stent stenosis, neoatherosclerosis, and increased bleeding led to the development of the novel DCBs. These DCBs have become well established in treating various clinical cases such as in-stent restenosis, de-novo small-vessel disease, bifurcation lesions, large-vessel disease, high bleeding risk, acute coronary syndromes, and diabetes mellitus.
Real-world outcomes of 600 drug-coated balloon angioplasties.
J Vasc Access
August 2025
Vascular Surgery, University of Insubria, Asst-settelaghi Universitary Teaching Hospital, Varese, Italy.
Introduction: The principal challenge in maintaining functional vascular access for hemodialysis is managing outflow stenoses, which are primarily caused by intimal hyperplasia. These stenoses are the leading cause of access dysfunction, leading to inadequate dialysis, increased morbidity, and frequent reinterventions. While drug-coated balloons (DCBs) have emerged as a promising solution by delivering antiproliferative agents to reduce restenosis rates, further clinical insights are needed to establish their role in vascular access management.
View Article and Find Full Text PDF